Standout Papers
Citation Impact
Citing Papers
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
2017
Randomized Phase II Trial of Concurrent Cisplatin-Radiotherapy With or Without Neoadjuvant Docetaxel and Cisplatin in Advanced Nasopharyngeal Carcinoma
2008
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx— ECOG-ACRIN Cancer Research Group
2017
Induction Chemotherapy and Cetuximab for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results From a Phase II Prospective Trial
2009
The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma
2009
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
2010 Standout
The biomarkers of human papillomavirus infection in tonsillar squamous cell carcinoma—molecular basis and predicting favorable outcome
2008
Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions
2018
Gastric cancer
2016 Standout
Head and neck squamous cell carcinoma
2020 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Current clinical outcomes demand new treatment options for SCCHN
2005
Chemoprevention targets for tobacco-related head and neck cancer: Past lessons and future directions
2015
Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: A prospective study
1995
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
2012 Standout
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
2016 Standout
The value of quality-of-life questionnaires in head and neck cancer
2012
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
2014 Standout
mTOR co-targeting strategies for head and neck cancer therapy
2017
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
2013 Standout
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
2017
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
2013
The biology and management of non-small cell lung cancer
2018 StandoutNature
Quality Assessment in Supportive Care in Head and Neck Cancer
2019
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Intraoperative diagnostics and elimination of residual microtumours with plasmonic nanobubbles
2016
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment
2016 Standout
Head and neck cancer
2008 Standout
Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies
2014
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site
2011
Nasopharyngeal carcinoma
2019 Standout
Improved Survival of Patients With Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial
2008 Standout
Tumor Cell Metabolism: Cancer's Achilles' Heel
2008 Standout
Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma
2012
Antibodies in oncology
2011
The molecular biology of head and neck cancer
2010 Standout
EGF–ERBB signalling: towards the systems level
2006 Standout
Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
2020
LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
2021 StandoutNobel
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
2009 Standout
Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials
2015
A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice
2020 StandoutNobel
Hyperfractionated Accelerated Radiotherapy for T1,2 Glottic Carcinoma
2008
Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
2015
Antibody therapy of cancer
2012 Standout
HPV-associated head and neck cancer: a virus-related cancer epidemic
2010 Standout
A morphometric study of liver cell dysplasia
1988
Randomized Trial of Induction Chemotherapy With Cisplatin and 5-Fluorouracil With or Without Docetaxel for Larynx Preservation
2009
Induction Chemotherapy in Locally Advanced Head and Neck Cancer: A New Standard of Care?
2008
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
2001 Standout
Inflammatory cell infiltration of tumors: Jekyll or Hyde
2007
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
2004 Standout
Drug repurposing: progress, challenges and recommendations
2018 Standout
Molecular Aspects of Head and Neck Cancer Therapy
2015
Treatment choice for locally advanced head and neck cancers on the basis of risk factors: biological risk factors
2012
Nasopharyngeal carcinoma
2015 Standout
The chemoradiation paradigm in head and neck cancer
2007
A randomized trial of induction docetaxel–cisplatin–5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02)
2017
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
2010 Standout
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
2020
Genomic insights into head and neck cancer
2016
Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas
2007
The course of health-related quality of life in head and neck cancer patients treated with chemoradiation: A prospective cohort study
2014
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Targeting Epidermal Growth Factor Receptor in Head and Neck Cancer
2022
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
2009
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Cardiovascular Complications of Cancer Therapy
2009
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer
2017 Standout
Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
2019
Microenvironmental regulation of metastasis
2008 Standout
Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials
2014
Hepatocellular carcinoma
1991
Laryngeal preservation in head and neck cancer: multidisciplinary approach
2006
Locally advanced head and neck squamous cell cancer: treatment choice based on risk factors and optimizing drug prescription
2012
The molecular landscape of head and neck cancer
2018 Standout
Concurrent Chemo-Radiation With or Without Induction Gemcitabine, Carboplatin, and Paclitaxel: A Randomized, Phase 2/3 Trial in Locally Advanced Nasopharyngeal Carcinoma
2015
The anti-angiogenic basis of metronomic chemotherapy
2004 Standout
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients
2009 Standout
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
2013
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and Radiotherapy
2009
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial
2011
Controversies in the Management of Oropharynx Cancer
2008
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Taxane-Cisplatin-Fluorouracil As Induction Chemotherapy in Locally Advanced Head and Neck Cancers: An Individual Patient Data Meta-Analysis of the Meta-Analysis of Chemotherapy in Head and Neck Cancer Group
2013
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
Eurogin Roadmap: Comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix
2013
Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy
2007
Immune‐checkpoint molecules on regulatory T‐cells as a potential therapeutic target in head and neck squamous cell cancers
2020
Head and Neck Cancer
2020 Standout
Magnesium in Man: Implications for Health and Disease
2014 Standout
Palifermin Reduces Severe Mucositis in Definitive Chemoradiotherapy of Locally Advanced Head and Neck Cancer: A Randomized, Placebo-Controlled Study
2011
Activated HGF-c-Met Axis in Head and Neck Cancer
2017
Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma
2013
Genetic Landscape of Human Papillomavirus–Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors
2015
Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer
2012 Standout
Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity
2014
Terminology of nodular hepatocellular lesions
1995 Standout
Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape
2010
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
2014 Standout
Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies
2011
Gene targets of sulforaphane in head and neck squamous cell carcinoma
2019
A Comparative Analysis of Low-Dose Metronomic Cyclophosphamide Reveals Absent or Low-Grade Toxicity on Tissues Highly Sensitive to the Toxic Effects of Maximum Tolerated Dose Regimens
2004
Concurrent Chemoradiotherapy for Locally Advanced, Nonmetastatic, Squamous Carcinoma of the Head and Neck: Consensus, Controversy, and Conundrum
2006
Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
2011
Immunology and Immunotherapy of Head and Neck Cancer
2015
Epidemiology of Human Papillomavirus–Positive Head and Neck Squamous Cell Carcinoma
2015 Standout
Phase II Trial of Chemoradiation for Organ Preservation in Resectable Stage III or IV Squamous Cell Carcinomas of the Larynx or Oropharynx: Results of Eastern Cooperative Oncology Group Study E2399
2007
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
2017 Standout
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
2015 Standout
Durable Long-Term Remission With Chemotherapy Alone for Stage II to IV Laryngeal Cancer
2009
Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2017
Prognostic role of epidermal growth factor receptor in head and neck cancer: A meta-analysis
2013
Predictors of Competing Mortality in Advanced Head and Neck Cancer
2009
Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522
2014
Liver cell dysplasia: What is its significance?
1987
Works of Éva Remenár being referenced
Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323)
2010
Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: Rationale for future randomised trials in human papilloma virus-negative disease
2012
Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III–IV unresectable head and neck cancer
2015
Radiotherapy and concurrent low-dose paclitaxel in locally advanced head and neck cancer
2003
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study
2010
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
2008 Standout
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
2007 Standout
A randomized phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and 5-fluorouracil (TPF) versus neoadjuvant PF in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN). Final analysis of EORTC 24971
2006
[Causal association between human papilloma virus infection and head and neck and esophageal squamous cell carcinoma].
2002
Neoadjuvant Immunotherapy of Oral Squamous Cell Carcinoma Modulates Intratumoral CD4/CD8 Ratio and Tumor Microenvironment: A Multicenter Phase II Clinical Trial
2005
Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME)
2006
Antiangiogenic Effects of Radiotherapy but not Initial Microvessel Density Predict Survival in Inoperable Oropharyngeal Squamous Cell Carcinoma
2006
Clinicopathological studies of liver cirrhosis and hepatocellular carcinoma in a general hospital
1981
Impact on quality of life (QoL) of the addition of docetaxel (T) to neoadjuvant cisplatin plus 5-fluorouracil treatment in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN): EORTC study 24971
2006
Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head andneck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971)
2004